P.0315 Association between hazardous alcohol use and initiation of naltrexone treatment for opioid use disorder among hiv-positive persons in russia

2021 ◽  
Vol 53 ◽  
pp. S228-S229
Author(s):  
M. Vetrova ◽  
E.A. Blokhina ◽  
D.M. Cheng ◽  
V. Truong ◽  
E.K. Quinn ◽  
...  
2017 ◽  
Vol 41 (S1) ◽  
pp. S639-S639
Author(s):  
G. Spies ◽  
G. Hoddinott ◽  
N. Beyers ◽  
S. Seedat

IntroductionThere is significant evidence that HIV is brain degenerative and long-term infection can impair cognitive functioning. In South Africa, alcohol remains the dominant substance of abuse and lifetime alcohol dependence has been found to impair memory, executive function and visuospatial capabilities. The individual liability of alcohol and HIV on neurocognitive function have been well demonstrated, however there is relatively little evidence of the potentially aggravating effects of this dual burden on neurocognitive outcomes.ObjectivesThe present study is ongoing and sought to identify the effects of hazardous alcohol use on neurocognitive functioning in the context of HIV infection.AimsTo describe the association between HIV and harmful alcohol use on neuropsychological test performance in a cohort of adults in the Western Cape of South africa.Methodsparticipants (n = 50) were tested using a battery of neuropsychological tests sensitive to the effects of HIV on the brain. Self-reported alcohol use was recorded using the alcohol use identification test (AUDIT). Results The sample consisted of 47 females and 3 males. All participants were HIV-positive and on antiretroviral therapy. A total of 23 (46%) participants reported no alcohol use and 27 (54%) reported drinking alcohol on the AUDIT.Resultsrevealed a significant difference between groups on the Stroop colour word test, with poorer performance evident among the alcohol users (P = 0.008).ConclusionAlcohol use in the context of HIV infection contributes to poorer executive function. These preliminary data provide evidence for a synergistic relationship between HIV infection and alcohol use.Disclosure of interestThe authors have not supplied their declaration of competing interest.


Author(s):  
Kara Manning ◽  
Andrew H. Rogers ◽  
Justin M. Shepherd ◽  
Cameron Matoska ◽  
Joseph W. Ditre ◽  
...  

Author(s):  
Lisa R. Miller-Matero ◽  
Julia Orlovskaia ◽  
Leah M. Hecht ◽  
Jordan M. Braciszeweski ◽  
Kellie M. Martens ◽  
...  

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Janja Jazbar ◽  
Igor Locatelli ◽  
Mitja Kos

Abstract Background Understanding potentially modifiable factors that influence the risk of frailty is a key concern for the management of this urgent contemporary public health challenge. This study evaluates the association between the use of various medications or alcohol and the incidence of frailty among older adults. Methods This study was a retrospective cohort study on older adults (≥ 65 years) using data from the longitudinal Survey of Health, Ageing and Retirement in Europe (SHARE survey, 28 countries). Medication use was measured as taking several different groups of medications. Alcohol use was assessed with SHARE questions corresponding to AUDIT-C. The outcome measure was the incidence of frailty after two years, defined by frailty index (FI) and frailty phenotype (FP). A multiple logistic regression model was used to evaluate the association with adjustment for several potential confounding factors. Results Of the 14,665 FI-population participants, 1800 (12.3%) developed frailty within two years. Of the 8133 FP-population participants, 2798 (34.4%) developed pre-frailty and 247 (3.0%) developed frailty within two years of baseline. After adjustment for potential confounding variables, non-hazardous alcohol use (adjusted OR; 95% CI for the FI-population: 0.68; 0.60–0.77) and hazardous alcohol use (0.80; 0.68–0.93) are associated with lower incidence of frailty compared to no alcohol use. The odds of frailty are increased when taking medications; the largest effect size was observed in older adults taking medication for chronic bronchitis (adjusted OR; 95% CI for the FI-population: 2.45; 1.87–3.22), joint pain and other pain medication (2.26; 2.00–2.54), medication for coronary and other heart disease (1.72; 1.52–1.96), medication for diabetes (1.69; 1.46–1.96), and medication for anxiety, depression and sleep problems (1.56; 1.33–1.84). Additionally, the risk of frailty was increased with stroke, Parkinson’s disease and dementia. Conclusions Taking certain groups of medication was associated with increased incidence of frailty and pre-frailty, which might be due to either medication use or the underlying disease. Alcohol use was associated with a lower risk of pre-frailty and frailty compared to no alcohol use, which might be due to reverse causality or residual confounding. There was no significant interaction effect between medication groups and alcohol use on frailty incidence.


2000 ◽  
Vol 19 (3) ◽  
pp. 291-298 ◽  
Author(s):  
G. K. Hulse ◽  
J. B. Saunders ◽  
R. M. Roydhouse ◽  
T. R. Stockwell ◽  
M. R. Basso

Sign in / Sign up

Export Citation Format

Share Document